Cidel Asset Management Inc. Increases Stock Holdings in Pfizer Inc. $PFE

Cidel Asset Management Inc. raised its stake in Pfizer Inc. (NYSE:PFE) by 3.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76,777 shares of the biopharmaceutical company’s stock after purchasing an additional 2,373 shares during the period. Cidel Asset Management Inc.’s holdings in Pfizer were worth $1,861,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. GKV Capital Management Co. Inc. acquired a new position in Pfizer during the first quarter worth approximately $27,000. North Capital Inc. acquired a new position in Pfizer during the first quarter worth approximately $28,000. Bayforest Capital Ltd acquired a new position in Pfizer during the first quarter worth approximately $28,000. Harbor Asset Planning Inc. acquired a new position in Pfizer during the second quarter worth approximately $29,000. Finally, Horizon Financial Services LLC acquired a new position in Pfizer during the first quarter worth approximately $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on PFE shares. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley decreased their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. UBS Group reiterated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Finally, Bank of America upped their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.13.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $24.52 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $29.36. The firm has a market capitalization of $139.38 billion, a PE ratio of 13.04, a P/E/G ratio of 0.81 and a beta of 0.55. The business has a 50-day moving average of $24.89 and a two-hundred day moving average of $24.11.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the firm earned $0.60 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer’s dividend payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.